Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

10 Things For Pfizer's New CEO To Worry About

Oct 16 2018

• By Bridget Silverman

Albert Bourla — Albert Bourla takes the CEO reins at Pfizer Jan. 1.

Related Content

Pfizer Agrees To Oversight Of Charitable Assistance Programs In DOJ Settlement

May 25 2018

Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says

Apr 11 2018

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

Jul 11 2018

Pfizer Expects Rebate Reform By HHS Will Extend Quickly To Private Market

Aug 01 2018

Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi

Jul 16 2018

Pfizer Deals Consumer Health Its Own Hand, Plays Waiting Game For Bids

Jul 11 2018

Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J

Sep 23 2018

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

Oct 01 2018

Gottlieb On Gene Therapies: 'Very Seductive' To Think About Accelerated Approval Pathway

May 07 2018

UK Changes Approach To Trials In Patients With Prior ATMP Therapy

Aug 29 2018

Pfizer Remains Flexible On Consumer Health In Restructuring

Aug 01 2018

Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra

Dec 14 2017

Pfizer's Xeljanz Approval In UC Includes Postmarket Study On Long-Term Effects

Jun 03 2018

Pfizer's Xeljanz Pushed By New Tailwind From Approval In Ulcerative Colitis

May 30 2018

Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products

Oct 02 2018

Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry

Jan 09 2018

Pfizer Eyes First-To-Market Opportunity In Alopecia

Sep 18 2018

Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up

Sep 12 2018

Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

Sep 12 2018

Pfizer/Merck KgAA Move Fast With Bid For Bavencio/Inlyta In Kidney Cancer Market

Sep 12 2018

Can Takeda's Alunbrig Take On Roche's Alecensa In First-Line ALK-Positive Lung Cancer?

Sep 27 2018

From Interchangeability To Exclusivity: US FDA Looks For Ways To Make Biologics Market More Competitive

Sep 07 2018

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

May 22 2018

Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain

Aug 16 2018

Pfizer, Astellas Accelerate Xtandi's Timeline In Early Prostate Cancer

Aug 24 2018

Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?

Jul 18 2018

Related Companies

Pfizer Inc.

Merck & Co., Inc.

Eli Lilly and Company

Incyte Corporation

AstraZeneca PLC

Novartis AG

Amgen, Inc.

Advanced Accelerator Applications SA

Sun Pharmaceutical Industries Ltd.

Array BioPharma, Inc.

Johnson & Johnson

Merck KGaA

Roche Holding AG

Takeda Pharmaceutical Co. Ltd.

Gilead Sciences, Inc.

Bristol Myers Squibb Company

Regeneron Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd.

Spark Therapeutics, Inc.

Additional Topics

United States Strategy Companies Drug Review Commercial BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window